Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rezenopy is a high-dose nasal spray formulation of naloxone hydrochloride, an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients. It works by competitively binding to opioid receptors, thereby reversing the life-threatening effects of opioids such as respiratory depression, sedation, and hypotension. Rezenopy delivers 10 mg of naloxone in a single-use pre-filled intranasal device—the highest strength available on the market—and is intended for immediate administration by laypersons or first responders in community settings where opioids may be present. It is not a substitute for emergency medical care; medical assistance should be sought immediately after use. The product was developed to address increasing rates of overdose involving high-potency synthetic opioids[1][2][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rezenopy.